Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan
- DOI
- 10.3389/fneur.2026.1827022
- Published
- 2026-05-13
- Container
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fneur.2026.1827022,
title = {Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan},
author = {Hideyo Kasai and Taro Yasumoto and Shota Kosuge and Ayako Osanai and Keita Mizuma and Akinori Futamura and Takeshi Kuroda and Kenjiro Ono and Hidetomo Murakami},
year = {2026},
journal = {Frontiers in Neurology},
doi = {10.3389/fneur.2026.1827022},
url = {https://doi.org/10.3389/fneur.2026.1827022}
}RIS
TY - JOUR TI - Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan AU - Hideyo Kasai AU - Taro Yasumoto AU - Shota Kosuge AU - Ayako Osanai AU - Keita Mizuma AU - Akinori Futamura AU - Takeshi Kuroda AU - Kenjiro Ono AU - Hidetomo Murakami PY - 2026 JO - Frontiers in Neurology DO - 10.3389/fneur.2026.1827022 UR - https://doi.org/10.3389/fneur.2026.1827022 ER -
APA
Kasai, H., Yasumoto, T., Kosuge, S., Osanai, A., Mizuma, K., Futamura, A., Kuroda, T., Ono, K., & Murakami, H. (2026). Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan. Frontiers in Neurology. https://doi.org/10.3389/fneur.2026.1827022
Source records
- crossref · retrieved 2026-09-25T20:27:00.182Z